» Articles » PMID: 18584575

The Efficacy of Acamprosate and Naltrexone in the Treatment of Alcohol Dependence: a Relative Benefits Analysis of Randomized Controlled Trials

Overview
Publisher Informa Healthcare
Specialty Psychiatry
Date 2008 Jun 28
PMID 18584575
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Random controlled trials on the efficacy of naltrexone and acamprosate in the treatment of alcohol dependence were reviewed, using a Relative Benefit (RB) analysis approach. A total of 42 studies were included, showing acamprosate use demonstrated a modest improvement, with a RB of 1.76 at three month follow-up. Short-term administration of naltrexone significantly reduced the relapse rate, but was not associated with modification in the abstinence rate. There was insufficient data available to ascertain the efficacy of naltrexone and acamprosate over prolonged periods of time, or the effectiveness of the medications relative to each other.

Citing Articles

Which interventions for alcohol use should be included in a universal healthcare benefit package? An umbrella review of targeted interventions to address harmful drinking and dependence.

Botwright S, Sutawong J, Kingkaew P, Anothaisintawee T, Dabak S, Suwanpanich C BMC Public Health. 2023; 23(1):382.

PMID: 36823618 PMC: 9948368. DOI: 10.1186/s12889-023-15152-6.


Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.

Hyland C, McDowell M, Bain P, Huskamp H, Busch A J Subst Abuse Treat. 2022; 144:108919.

PMID: 36332528 PMC: 10321472. DOI: 10.1016/j.jsat.2022.108919.


Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants.

Thompson S, Gianessi C, OMalley S, Cavallo D, Shi J, Tetrault J Front Psychiatry. 2021; 12:709559.

PMID: 34531767 PMC: 8438169. DOI: 10.3389/fpsyt.2021.709559.


Facilitating rapid access to addiction treatment: a randomized controlled trial.

Srivastava A, Clarke S, Hardy K, Kahan M Addict Sci Clin Pract. 2021; 16(1):34.

PMID: 34034821 PMC: 8152083. DOI: 10.1186/s13722-021-00240-y.


Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial.

Antonsen K, Klausen M, Brunchmann A, Le Dous N, Jensen M, Miskowiak K BMJ Open. 2018; 8(7):e019562.

PMID: 30012779 PMC: 6082448. DOI: 10.1136/bmjopen-2017-019562.